Leithner A, Gapp M, Radl R, Pascher A, Krippl P, Leithner K, Windhager R, Beham A
Department of Orthopaedic Surgery, Medical University Graz, Auenbruggerplatz 5, A-8036 Graz, Austria.
J Clin Pathol. 2005 Nov;58(11):1152-6. doi: 10.1136/jcp.2005.026278.
BACKGROUND/AIMS: Although the standard treatment for desmoid tumours is complete surgical resection with wide margins, the optimal adjuvant treatment for recurrent or inoperable disease is unclear, often being based on sporadic immunohistochemical reports with a low number of cases. Therefore, a large immunohistochemical study was performed, to provide a theoretical basis for adjuvant treatment regimens.
One hundred and sixteen tissue samples from 80 patients (49 female, 31 male; mean age, 34 years; range, 0-83) with desmoid tumours (46 extra-abdominal, 21 abdominal, 13 intra-abdominal) were tested for oestrogen receptors alpha and beta, progesterone and androgen receptors, and somatostatin, in addition to HER2, cathepsin D, Ki-67, and c-KIT by immunohistochemistry.
All samples were negative for oestrogen receptor alpha, HER2, and the progesterone receptor. Positive staining for the androgen receptor was found in six extra-abdominal cases. Staining for oestrogen receptor beta was positive in four extra-abdominal, two abdominal, and one intra-abdominal case. Staining for somatostatin was positive in six extra-abdominal, two abdominal, and one intra-abdominal case, and staining for cathepsin D was positive in all cases. Positive staining for Ki-67 was found in 14 extra-abdominal, three abdominal, and three intra-abdominal cases. C-KIT was detectable in one abdominal case only.
The data from this immunohistochemical study show that the published effects of antioestrogens and imatinib mesylate in the treatment of aggressive fibromatoses may not be attributable to oestrogen receptor alpha or c-KIT expression.
背景/目的:尽管韧带样瘤的标准治疗方法是进行切缘阴性的完整手术切除,但对于复发性或无法手术的疾病,最佳辅助治疗方法尚不清楚,通常基于少量病例的散发性免疫组化报告。因此,我们进行了一项大型免疫组化研究,为辅助治疗方案提供理论依据。
对80例韧带样瘤患者(49例女性,31例男性;平均年龄34岁;范围0 - 83岁)的116份组织样本(46例腹壁外、21例腹壁、13例腹腔内)进行免疫组化检测,检测雌激素受体α和β、孕激素和雄激素受体、生长抑素,以及HER2、组织蛋白酶D、Ki-67和c-KIT。
所有样本的雌激素受体α、HER2和孕激素受体均为阴性。在6例腹壁外病例中发现雄激素受体呈阳性染色。雌激素受体β染色在4例腹壁外、2例腹壁和1例腹腔内病例中呈阳性。生长抑素染色在6例腹壁外、2例腹壁和1例腹腔内病例中呈阳性,组织蛋白酶D染色在所有病例中均呈阳性。在14例腹壁外、3例腹壁和3例腹腔内病例中发现Ki-67呈阳性染色。仅在1例腹腔内病例中检测到c-KIT。
这项免疫组化研究的数据表明,已发表的抗雌激素和甲磺酸伊马替尼在侵袭性纤维瘤病治疗中的作用可能与雌激素受体α或c-KIT表达无关。